Johnson & Johnson 4th-qtr beats expectations

26 January 2016

US health care giant Johnson & Johnson (NYSE: JNJ) kicked off the fourth-quarter 2015 financial results reporting season for the sector, beating analysts’ expectations despite posting lower sales, and pushing its shares up 2.8% to $99.14 in mid-morning trading.

J&J said net income was $3.2 billion, or $1.15 per share, up 26.5% from $2.53 billion, or 89 cents per share, a year earlier. Adjusted net income was $4.04 billion, or $1.44 per share, beating Wall Street expectations for adjusted earnings of $1.42 per share, based on estimates of analysts surveyed by Zacks Investment Research.

However, group revenue fell 2.4% to $17.81 billion, impacted by unfavorable currency rates and below analysts’ expectations of $17.94 billion. Sales of prescription drugs edged 0.8% higher to $8.06 billion, while sales of consumer health products fell 7.9% to $3.32 billion. Sales of medical devices and diagnostic equipment fell 3.3% to $6.43 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK